CNS/Neurology Market Research Reports & Industry Analysis
A neurologist is a medical doctor that specializes in the diagnosis, treatment and management of illnesses affecting the brain, spinal cord, and nervous system. Neurologists must complete at least three years of specialized training in neurology, after completing medical school. A neurosurgeon must go through much more extensive and rigorous schooling and training. On top of diagnosing and treating neurological disorders, neurosurgeons can also perform surgery on the brain, spinal cord, and nerves.
Pharmaceuticals in CNS/Neurology are one of leading fields in medicine in terms of funding and research. On top of growing patient numbers, there remains a comparatively high unmet need in treatment of many neurological diseases. With the potential of being one of the most lucrative therapy areas in the future pharmaceutical Industry, Alzheimer's disease offers the greatest commercial opportunity for pharmaceutical companies in neurology. Many of the therapeutic drugs used to treat CNS/Neurological disorders have lost their patent protection or market exclusivity, leading to greater research and market opportunities for competing pharmaceutical and medical device companies. Despite the widespread use of CNS drugs, knowledge of these agents is limited due to the anatomic and neurochemical complexity of the brain and spinal cord.
CNS/Neurology Industry Research & Market Reports
-
Cranial Fixation and Stabilization Systems
... Billion by 2030, growing at a CAGR of 7.1% over the analysis period 2024-2030. Cranial Stabilization Systems, one of the segments analyzed in the report, is expected to record a 6.7% CAGR and reach US$987.5 ... Read More
-
Neurovascular Devices / Interventional Neurology
... Billion by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Aneurysm Coiling & Embolization Devices, one of the segments analyzed in the report, is expected to record a 8.2% CAGR and ... Read More
-
Neuroprotection Therapeutics
... CAGR of 6.9% over the analysis period 2024-2030. Free Radical Trapping Agents (Antioxidants), one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$45.7 Billion by the end ... Read More
-
Spinal Muscular Atrophy
... at a CAGR of 12.3% over the analysis period 2024-2030. Type 1 Spinal Muscular Atrophy, one of the segments analyzed in the report, is expected to record a 12.9% CAGR and reach US$2.4 Billion by ... Read More
-
Anxiolytics
... 4.6% over the analysis period 2024-2030. The U.S. Market is Estimated at US$259.8 Million While China is Forecast to Grow at 7.1% CAGR The Anxiolytics market in the U.S. is estimated at US$259.8 Million in ... Read More
-
Brain Tumor Diagnosis and Treatment
... Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2024-2030. Primary Brain Tumor, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$1.3 ... Read More
-
Cognitive Assessment and Training
... 2030, growing at a CAGR of 26.9% over the analysis period 2024-2030. Cognitive Assessment and Training Solutions, one of the segments analyzed in the report, is expected to record a 24.9% CAGR and reach US$17.4 ... Read More
-
Intracranial Pressure (ICP) Monitoring Devices
... Billion by 2030, growing at a CAGR of 6.1% over the analysis period 2024-2030. Invasive Devices, one of the segments analyzed in the report, is expected to record a 5.9% CAGR and reach US$2.4 Billion ... Read More
-
Intracranial Aneurysm
... CAGR of 8.7% over the analysis period 2024-2030. Endovascular Coiling, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$2.3 Billion by the end of the analysis ... Read More
-
Anxiety Disorder Treatment
... at a CAGR of 2.4% over the analysis period 2024-2030. Antidepressants, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$4.9 Billion by the end of the ... Read More
-
Narcolepsy Therapeutics
... CAGR of 7.1% over the analysis period 2024-2030. Narcolepsy with Cataplexy Therapeutics, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$1.9 Billion by the end of ... Read More
-
Contract Research Organization Services (CROs)
... Billion by 2030, growing at a CAGR of 10.6% over the analysis period 2024-2030. Clinical Research Services, one of the segments analyzed in the report, is expected to record a 11.4% CAGR and reach US$76.7 ... Read More
-
CNS Therapeutics
... CAGR of 7.3% over the analysis period 2024-2030. Neurodegenerative Diseases Therapeutics, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$75.9 Billion by the end of the ... Read More
-
Bipolar Disorder Therapeutics
... at a CAGR of 3.4% over the analysis period 2024-2030. Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$3.5 Billion by the end of ... Read More
-
Neurorehabilitation Devices
... CAGR of 16.5% over the analysis period 2024-2030. Neurorobotic Systems, one of the segments analyzed in the report, is expected to record a 18.7% CAGR and reach US$2.0 Billion by the end of the analysis ... Read More
-
Schizophrenia Therapeutics
... CAGR of 4.2% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 4.6% CAGR and reach US$7.7 Billion by the end of ... Read More
-
Interventional Neurology Devices
... at a CAGR of 4.6% over the analysis period 2024-2030. Cerebral Embolization & Aneurysm Coiling, one of the segments analyzed in the report, is expected to record a 4.8% CAGR and reach US$2.0 Billion by ... Read More
-
Opioids
... 2.3% over the analysis period 2024-2030. Extended-Release / Long-Acting Opioids, one of the segments analyzed in the report, is expected to record a 2.9% CAGR and reach US$18.7 Billion by the end of the analysis ... Read More
-
Psychiatric and Substance Abuse Hospitals
... Billion by 2030, growing at a CAGR of 4.7% over the analysis period 2024-2030. Alcoholism Rehabilitation Hospitals, one of the segments analyzed in the report, is expected to record a 4.7% CAGR and reach US$13.5 ... Read More
-
Biosimulation Market by Offering (Module, Integrated Platform), Application (Disease Modeling, PBPK, PKPD, Trial Simulation, Manufacturing & Supply chain: planning & forecasting), Indication (Cancer, CNS, CVS), End User, & Region - Global Forecast to 2029
... the drug development process has been one of the major drivers in the adoption of biosimulation tools. These tools predict how the drugs will behave inside the human body, potentially minimizing the requirements of extensive ... Read More
-
Amyotrophic Lateral Sclerosis
... at a CAGR of 19.4% over the analysis period 2024-2030. The U.S. Market is Estimated at US$345.9 Million While China is Forecast to Grow at 18.4% CAGR The Amyotrophic Lateral Sclerosis market in the U.S. ... Read More
-
Brain Implants
... CAGR of 10.6% over the analysis period 2024-2030. Deep Brain Stimulation, one of the segments analyzed in the report, is expected to record a 11.2% CAGR and reach US$8.7 Billion by the end of the ... Read More
-
Antipsychotic Drugs
... CAGR of 6.8% over the analysis period 2024-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 7.4% CAGR and reach US$15.7 Billion by the end of ... Read More
-
Brain Health Supplements
... at a CAGR of 5.4% over the analysis period 2024-2030. Natural Molecules, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$6.8 Billion by the end of ... Read More
-
Brain Computer Interface
... at a CAGR of 10.3% over the analysis period 2024-2030. Invasive BCI, one of the segments analyzed in the report, is expected to record a 11.6% CAGR and reach US$1.5 Billion by the end of ... Read More
Research Assistance
